DNLI News and Press, Denali Therapeutics Inc. From 06/10/21

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI ) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At UBS 2021 Global Healthcare Virtual Conference - Slideshow

Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's in...

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire CAMBRIDGE, Mass. , May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet'...

In President Joe Biden's first proposed budget to Congress, he requested authorization for spending increases in a number of areas. One of the most prominent was healthcare. Specifically, the president proposed a new agency within the National Institutes of Health (NIH) with a directive to ...

Denali Therapeutics (DNLI): Q1 GAAP EPS of -$0.58 misses by $0.21.Revenue of $7.9M (+119.4% Y/Y) misses by $23.72M.Shares +2.58% PM.Press Release For further details see: Denali Therapeutics EPS misses by $0.21, misses on revenue

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial re...

Denali Therapeutics (DNLI) announces final results from Phase 1 and 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen (BIIB) as a potential treatment of Parkinson’s disease.Safety and biomarker goals were met in both...